• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

家族性高胆固醇血症中的低密度脂蛋白受体基因座:多种突变破坏膜受体的转运和加工。

The LDL receptor locus in familial hypercholesterolemia: multiple mutations disrupt transport and processing of a membrane receptor.

作者信息

Tolleshaug H, Hobgood K K, Brown M S, Goldstein J L

出版信息

Cell. 1983 Mar;32(3):941-51. doi: 10.1016/0092-8674(83)90079-x.

DOI:10.1016/0092-8674(83)90079-x
PMID:6299582
Abstract

The receptor for low-density lipoprotein (LDL) is synthesized as a 120 kd precursor that undergoes a 40 kd posttranslational increase in apparent molecular weight en route to the cell surface. We describe seven mutations that disrupt synthesis, processing and transport of the receptor in fibroblasts from 77 subjects with the clinical diagnosis of homozygous familial hypercholesterolemia. One mutation obliterates synthesis of immunoprecipitable precursor. Three mutations specify precursors (100, 120 and 135 kd) that fail to undergo normal processing and fail to reach the cell surface. The other three mutations specify precursors (100, 120, and 170 kd) that undergo a normal 40 kd increase in molecular weight and reach the surface, but do not bind LDL normally. Pedigree studies show that each mutation segregates as an allele at the LDL receptor locus. These data imply that signals for transport of receptors from endoplasmic reticulum to the cell surface are contained within the amino acid sequences of the receptors, and that mutations affecting these sequences can disrupt receptor transport.

摘要

低密度脂蛋白(LDL)受体最初合成时是一种120kd的前体,在前往细胞表面的过程中,其表观分子量会在翻译后增加40kd。我们描述了7个突变,这些突变会干扰77名临床诊断为纯合子家族性高胆固醇血症患者的成纤维细胞中受体的合成、加工和运输。一个突变消除了可免疫沉淀前体的合成。三个突变产生的前体(100kd、120kd和135kd)无法进行正常加工,也无法到达细胞表面。另外三个突变产生的前体(100kd、120kd和170kd)分子量正常增加40kd并到达细胞表面,但不能正常结合LDL。家系研究表明,每个突变都作为LDL受体位点的一个等位基因进行分离。这些数据表明,受体从内质网运输到细胞表面的信号包含在受体的氨基酸序列中,影响这些序列的突变会破坏受体运输。

相似文献

1
The LDL receptor locus in familial hypercholesterolemia: multiple mutations disrupt transport and processing of a membrane receptor.家族性高胆固醇血症中的低密度脂蛋白受体基因座:多种突变破坏膜受体的转运和加工。
Cell. 1983 Mar;32(3):941-51. doi: 10.1016/0092-8674(83)90079-x.
2
Posttranslational processing of the LDL receptor and its genetic disruption in familial hypercholesterolemia.低密度脂蛋白受体的翻译后加工及其在家族性高胆固醇血症中的基因破坏。
Cell. 1982 Oct;30(3):715-24. doi: 10.1016/0092-8674(82)90276-8.
3
Kinetic defects in the processing of the low density lipoprotein receptor in fibroblasts from WHHL rabbits and a family with familial hypercholesterolemia.WHHL兔及一个家族性高胆固醇血症家族的成纤维细胞中低密度脂蛋白受体加工过程的动力学缺陷
Mol Biol Med. 1983 Oct;1(3):353-67.
4
A missense mutation in the low density lipoprotein receptor gene causes familial hypercholesterolemia in Sephardic Jews.
Hum Genet. 1993 Mar;91(2):141-7. doi: 10.1007/BF00222714.
5
Mutations of the low density lipoprotein receptor in Japanese kindreds with familial hypercholesterolemia.
Hum Genet. 1988 Jun;79(2):103-8. doi: 10.1007/BF00280546.
6
Deletion in the first cysteine-rich repeat of low density lipoprotein receptor impairs its transport but not lipoprotein binding in fibroblasts from a subject with familial hypercholesterolemia.低密度脂蛋白受体第一个富含半胱氨酸重复序列的缺失会损害其在家族性高胆固醇血症患者成纤维细胞中的转运,但不影响脂蛋白结合。
Proc Natl Acad Sci U S A. 1988 Nov;85(21):7912-6. doi: 10.1073/pnas.85.21.7912.
7
The LDL receptor in familial hypercholesterolemia: use of human mutations to dissect a membrane protein.
Cold Spring Harb Symp Quant Biol. 1986;51 Pt 2:811-9. doi: 10.1101/sqb.1986.051.01.094.
8
Two novel point mutations in the EGF precursor homology domain of the LDL receptor gene causing familial hypercholesterolemia.
Hum Genet. 1995 Aug;96(2):241-2. doi: 10.1007/BF00207391.
9
Immunocytochemical localization of mutant low density lipoprotein receptors that fail to reach the Golgi complex.未能抵达高尔基体复合体的突变型低密度脂蛋白受体的免疫细胞化学定位
J Cell Biol. 1988 Jun;106(6):1831-41. doi: 10.1083/jcb.106.6.1831.
10
FH-Freiburg: a novel missense mutation (C317Y) in growth factor repeat A of the low density lipoprotein receptor gene in a German patient with homozygous familial hypercholesterolemia.
Atherosclerosis. 2000 Aug;151(2):525-34. doi: 10.1016/s0021-9150(99)00415-3.

引用本文的文献

1
NPC1 as a novel therapeutic target for induction of pyroptosis in cancers.NPC1作为诱导癌症细胞焦亡的新型治疗靶点。
Biomark Res. 2025 Sep 26;13(1):115. doi: 10.1186/s40364-025-00823-w.
2
Influence of the IDOL Gene Variants on Low-Density Lipoprotein Cholesterol Levels in Turkish Patients with Familial Hypercholesterolemia.IDOL基因变异对土耳其家族性高胆固醇血症患者低密度脂蛋白胆固醇水平的影响。
Mol Syndromol. 2025 Apr;16(2):128-137. doi: 10.1159/000540898. Epub 2024 Aug 30.
3
Synergistic effects of mutation and glycosylation on disease progression.
突变与糖基化对疾病进展的协同作用。
Front Mol Biosci. 2025 Feb 4;12:1550815. doi: 10.3389/fmolb.2025.1550815. eCollection 2025.
4
Effect of diet and genotype on the lipidome of mice with altered lipoprotein metabolism.饮食和基因型对脂蛋白代谢改变的小鼠脂质组的影响。
iScience. 2024 Sep 26;27(10):111051. doi: 10.1016/j.isci.2024.111051. eCollection 2024 Oct 18.
5
LDL Transcytosis by the Arterial Endothelium-Atherosclerosis by a Thousand Cuts?动脉内皮细胞的 LDL 转胞吞作用——动脉粥样硬化的“千刀万剐”?
Curr Atheroscler Rep. 2023 Aug;25(8):457-465. doi: 10.1007/s11883-023-01118-x. Epub 2023 Jun 26.
6
Caveolin-1 and Atherosclerosis: Regulation of LDLs Fate in Endothelial Cells.窖蛋白-1 与动脉粥样硬化:内皮细胞中 LDL 命运的调节。
Int J Mol Sci. 2023 May 17;24(10):8869. doi: 10.3390/ijms24108869.
7
Familial hypercholesterolemia class II low-density lipoprotein receptor response to statin treatment.家族性高胆固醇血症 II 型患者对他汀类药物治疗的低密度脂蛋白受体反应。
Dis Model Mech. 2020 Apr 6;13(4):dmm042911. doi: 10.1242/dmm.042911.
8
Nutrigenetic Contributions to Dyslipidemia: A Focus on Physiologically Relevant Pathways of Lipid and Lipoprotein Metabolism.营养遗传学与血脂异常:关注脂质和脂蛋白代谢的生理相关途径。
Nutrients. 2018 Oct 2;10(10):1404. doi: 10.3390/nu10101404.
9
Pharmacoperones as Novel Therapeutics for Diverse Protein Conformational Diseases.药物共受体作为治疗多种蛋白构象疾病的新型疗法。
Physiol Rev. 2018 Apr 1;98(2):697-725. doi: 10.1152/physrev.00029.2016.
10
Ruxolitinib and Polycation Combination Treatment Overcomes Multiple Mechanisms of Resistance of Pancreatic Cancer Cells to Oncolytic Vesicular Stomatitis Virus.芦可替尼与聚阳离子联合治疗克服了胰腺癌细胞对溶瘤性水疱性口炎病毒的多种耐药机制。
J Virol. 2017 Jul 27;91(16). doi: 10.1128/JVI.00461-17. Print 2017 Aug 15.